AZD-1656

N/A

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameAZD-1656
Drug Alias NameAZD-1656
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlucokinase activators
TargetsGlucokinase
Therapy Area/IndicationsRejection of renal transplantationCoronavirus Disease 2019 (COVID-19)Hyperglycemia +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesSweden +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesClinConnect IncConduit Pharmaceuticals IncAstrazeneca Plc +[4] 
Inactive CompaniesSt George Street Capital Ltd
Active IndicationsRejection of renal transplantationDiabetes Mellitus, Type 2Kidney Failure, Chronic
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)HyperglycemiaDiabetes Mellitus, Type 1

Other Information

ATC CodeN/A
Related LinksN/A